Non-Myeloablative Allogeneic Transplantation / Edition 1by Asad Bashey
Pub. Date: 02/28/2002
Publisher: Springer US
Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem
Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.
Non-Myeloablative Allogeneic Transplantation will provide both practitioners and academic clinicians with a better understanding of underlying concepts, current methodologies, and results obtained by the pioneering centers for this rapidly evolving field.
Table of Contents
Contributors. Preface. 1. Development of allogeneic hematopoietic stem cell transplantation (HSCT); J. Castro, E.D. Ball. 2. Immunosuppression with limited toxicity: characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation; A. Bashey. 3. Mobilization of allogeneic peripheral blood progenitor cells; P. Law, T. Lane. 4. Non-myeloblative induction of mixed hematopoietic chimerism: application to transplantation tolerance and hematologic malignancies in experimental and clinical studies; M. Sykes, T. Spitzer. 5. Combined use of autografting and non-myeloablative allografting for the treatment of hematologic malignancies and metastatic breast cancer; A.M. Carella, E. Lerma, M. Cavaliere, M.T. Corsetti. 6. Non-myeloablative hematopoietic stem cell transplantation (NHT) in the treatment of human malignancies: from animal models to clinical practice; A. Shimoni, A. Nagler. 7. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy; I. Khouri, S. Giralt, R. Champlin. 8. Outpatient allografting in hematologic malignancies and nonmalignant disorders - applying lessons learned in the canine model to humans; M. Maris, R.F. Storb. 9. Non-myeloablative transplants for congenital diseases; J. Donahue, E. Carrier. Index.
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >